Cost-effectiveness of ranibizumab and aflibercept to treat diabetic macular edema from a U.S. perspective: analysis of 2-year Protocol T data.
Conclusions: This analysis suggests that aflibercept is not cost-effective versus ranibizumab for patients with DME, regardless of baseline vision.
PMID: 31502893 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
More News: Avastin | Diabetes | Economics | Endocrinology | Health Management | Lucentis | Medicare | Ranibizumab Injection | Study